Trump says Iran war "close to over" amid hopes for more negotiations
Investing.com - RBC Capital reiterated an Underperform rating and $25.00 price target on Pfizer stock (NYSE:PFE), citing mixed expectations for key products and a challenging start to 2026. The stock currently trades at $27.15, while analyst consensus stands at Hold with price targets ranging from $25 to $36.
The firm forecasts first-quarter 2026 revenues approximately 4% below consensus, driven by three key products: Prevnar, Paxlovid, and Vyndamax. Vyndamax has experienced gross pricing erosion for six consecutive quarters as competitive pressures build.
Paxlovid faces ongoing demand challenges. For Prevnar, while contracts will ultimately drive sales, prescription trends show increasing competition from Merck’s Capvaxive.
RBC Capital views the upcoming Vyndamax bench trial on April 27 as the next significant catalyst. The firm also highlighted sigvotatug vedotin second-line lung Phase 3 data expected in the second quarter of 2026 as another key event.
Both catalysts present upside potential, the firm noted.
In other recent news, Pfizer Inc. has been involved in several significant developments. A Brussels court ruled that Poland and Romania must honor their COVID vaccine purchase agreements with Pfizer, valued at $2.2 billion, which will require delivery over the next few years. Additionally, Pfizer completed its exit from ViiV Healthcare, with Shionogi increasing its stake to 21.7% through a $2.125 billion purchase, while Pfizer received $1.875 billion from this transaction. GSK retained its majority interest in ViiV Healthcare, and a special dividend of $250 million was paid to GSK.
In the realm of drug trials, Guggenheim raised its price target on Pfizer to $36, maintaining a Buy rating, based on expectations for Pfizer’s MEVPRO-1 Phase 3 trial in prostate cancer, which is anticipated to yield results in the second half of 2026. Furthermore, Pfizer and Valneva announced that their Lyme disease vaccine candidate demonstrated 73.2% efficacy in a Phase 3 trial. Pfizer also issued a warning to shareholders about a mini-tender offer by Tutanota LLC, which proposes to buy up to 1 million shares at $32.00 each, potentially below market value. These developments highlight the various strategic and operational activities Pfizer is currently engaged in.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.